Treatment with exenatide once weekly or twice daily for 30 weeks is
associated with changes in several cardiovascular risk markers

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

Bibliographic Details
Main Authors:	Chiquette, Elaine, Toth, Peter P, Ramirez, Gilbert, Cobble, Michael, Chilton, Robert
Format:	Online
Language:	English
Published:	Dove Medical Press 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500143/

Similar Items

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
by: Ji, Linong, et al.
Published: (2013)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
by: Ridge, T, et al.
Published: (2012)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
by: Goud, Aditya, et al.
Published: (2015)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
by: Macdougall, Iain C
Published: (2007)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
by: Davies, Melanie, et al.
Published: (2013)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
by: Blevins, Thomas, et al.
Published: (2016)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
by: Wysham, C, et al.
Published: (2011)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
by: Onishi, Yukiko, et al.
Published: (2012)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
by: Rosenstock, Julio, et al.
Published: (2013)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
by: Wang, Bruce, et al.
Published: (2015)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders, William B, et al.
Published: (2016)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
by: Simó, Rafael, et al.
Published: (2015)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
by: Ciszek, Michał
Published: (2013)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
by: Rosenstock, Julio, et al.
Published: (2013)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
by: Mathieu, Chantal, et al.
Published: (2013)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
by: Blonde, Lawrence, et al.
Published: (2015)

Once and Twice
by: Richard S. Kayne
Published: (2015-05-01)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
by: Alshali, Khalid Z., et al.
Published: (2016)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
by: Diamant, Michaela, et al.
Published: (2012)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
by: Sension, M, et al.
Published: (2010)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
by: Gaebler, Julia A, et al.
Published: (2012)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
by: Taylor, Kristin, et al.
Published: (2011)

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
by: Pencek, R, et al.
Published: (2012)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
by: MacConell, Leigh, et al.
Published: (2013)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann, Katherine V, et al.
Published: (2014)

Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
by: Grossman, Samuel S.
Published: (2014)

Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
by: Deng, Wuquan, et al.
Published: (2015)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
by: MacConell, Leigh, et al.
Published: (2015)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
by: Meloni, Alison R, et al.
Published: (2013)

Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study
by: OHTA, SHOICHIRO, et al.
Published: (2014)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Published: (2015)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
by: Sugimoto, T., et al.
Published: (2013)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
by: Henry, Robert R., et al.
Published: (2013)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
by: Molina, Jean-Michel, et al.
Published: (2014)

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies
by: Feldman, Gregory J, et al.
Published: (2014)

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
by: Koch, Andrea, et al.
Published: (2014)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
by: Tatarkiewicz, K, et al.
Published: (2013)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
by: Shiraki, M., et al.
Published: (2016)

A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
by: Lee, Joo-Heung, et al.
Published: (2016)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
by: Tobin, G S, et al.
Published: (2012)